Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Frank J. Bruns is active.

Publication


Featured researches published by Frank J. Bruns.


The American Journal of Medicine | 2000

A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients

Srinivasan Beddhu; Frank J. Bruns; Melissa I. Saul; Patricia Seddon; Mark L. Zeidel

PURPOSE In a university-based dialysis program, we found that 25% of the patients accounted for 50% of the costs and 42% of the deaths. We determined whether the Charlson Comorbidity Index, a simple measure of comorbid conditions, could predict clinical outcomes and costs in these patients. METHODS Patients on hemodialysis or peritoneal dialysis from July 1996 to June 1998 at the University of Pittsburgh outpatient dialysis unit were studied. Comorbidity scores and outcomes were determined by reviewing the Medical Archival Retrieval System database and outpatient records. RESULTS Two hundred sixty-eight patients were observed for 293 patient-years. The Comorbidity Index strongly predicted admission rate (relative risk per each unit increase = 1.20; 95% confidence interval [CI]: 1.16 to 1.23, P = 0.0001), hospital days and inpatient costs (both P <0.0001), and mortality (relative risk per unit increase = 1.24, 95% CI: 1.11 to 1.39, P = 0.0002.). Age and diabetes, used in the Health Care Financing Administration dialysis capitation model, correlated poorly with outcomes. CONCLUSIONS The modified Charlson Comorbidity Index predicts outcomes and costs in dialysis patients. This index may be useful in determining appropriate payment for care of dialysis patients under capitated payment schemes and as a research tool to stratify dialysis patients in order to compare the outcomes of various interventions.


The American Journal of the Medical Sciences | 1978

Control of cholesterol embolization by discontinuation of anticoagulant therapy.

Frank J. Bruns; David P. Segel; Sheldon Adler

A 64-year-old man developed multisystem disease including renal failure while receiving anticoagulants. Renal biopsy showed cholesterol embolization. Discontinuation of anticoagulants resulted in prompt cessation of symptoms and dramatic improvement in renal function.


American Journal of Kidney Diseases | 1985

AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: PRESENTATION, COMPLICATIONS, AND PROGNOSIS

Vera B. Delaney; Sheldon Adler; Frank J. Bruns; Michael Licinia; David P. Segel; Donald S. Fraley

Fifty-three symptomatic adults with autosomal dominant polycystic kidney disease were studied retrospectively for a mean follow-up of 12 years (range 10 months to 33 years). Diagnosis was confirmed by either x-ray, ultrasound, laparotomy, or autopsy. Commonest presenting clinical findings were flank pain (30%), hypertension (21%), symptomatic urinary tract infection (UTI) (19%), gross hematuria (19%), and palpable masses (15%). A total of nine patients (17%) progressed to end-stage renal disease. Change in renal function measured using the reciprocal of plasma creatinine plotted against time was linear for each individual patient with a maximum functional decline of 0.7 mg/dL/yr (slope = -0.07). Past the age of sixty renal failure was uncommon. Easily controlled hypertension developed in 64% attended by mild retinopathy. UTIs were common (53%), often recurrent (61%), precipitated by instrumentation in 6 of 14 patients (43%), leading to death in two (33%). Renal calculi were extremely common (34%) and had no defined metabolic cause. The presence of hematuria (64%), gross or microscopic, bore no relationship to the decline in renal function. Pregnancy was normal in these patients with no increase in fetal or maternal morbidity or mortality. We conclude the following: Renal functional deterioration is linear, less than previously reported, and bears no relationship to hematuria. Hypertension is common, easily treated, and causes minor end-organ damage. Renal calculi are frequent. Urinary tract instrumentation often induces infection with considerable morbidity and mortality and must be avoided. Pregnancy is not contraindicated if renal function is normal. The prognosis for survival in this disease is better than previously reported.


The American Journal of Medicine | 2002

The effects of comorbid conditions on the outcomes of patients undergoing peritoneal dialysis

Srinivasan Beddhu; Mark L. Zeidel; Melissa I. Saul; Patricia Seddon; Matthew H. Samore; Gregory J. Stoddard; Frank J. Bruns

PURPOSE Dialysis patients frequently have comorbid conditions. We examined the effects of age and comorbid conditions on technique failure (i.e., transfer to hemodialysis), death, hospital costs, and kidney transplantation in patients treated with peritoneal dialysis. METHODS We studied 97 patients who began peritoneal dialysis from January 1, 1993, to December 31, 1998, at the University of Pittsburgh outpatient dialysis unit. Demographic characteristics, comorbid conditions, and outcomes were determined by reviewing the Medical Archival Retrieval System database and outpatient records. Because the comorbidity (Charlson) score was colinear with age, we used a modified version of the score without an age component. Low, moderate, and high comorbidity groups were defined based on the 33rd and 66th percentiles of the comorbidity score. RESULTS In multivariate-adjusted models, each decade increase in age was associated with an increased risk of death (hazard ratio [HR] = 1.7; 95% confidence interval [CI]: 1.1 to 2.5) and technique failure (HR = 1.5; 95% CI: 1.0 to 2.3). High (versus low) comorbidity was associated with an increased risk of death or technique failure (HR = 3.5; 95% CI: 1.0 to 12) and significantly higher average inpatient costs. There were no differences in age or comorbidity score between patients who transferred to hemodialysis and those who died. CONCLUSION Patients who are older and more ill have a greater risk of death and of transfer to hemodialysis from peritoneal dialysis.


The New England Journal of Medicine | 1980

Stimulation of Lactate Production by Administration of Bicarbonate in a Patient with a Solid Neoplasm and Lactic Acidosis

Donald S. Fraley; Sheldon Adler; Frank J. Bruns; Barbara Zett

LACTIC acidosis associated with acute leukemia has been attributed to overproduction of lactic acid by the tumor cells, 1 2 3 whereas lactic acidosis in solid, nonhematologic neoplasia with hepatic...


Annals of Internal Medicine | 1991

Sustained remission of membranous glomerulonephritis after cyclophosphamide and prednisone.

Frank J. Bruns; Sheldon Adler; Donald S. Fraley; David P. Segel

OBJECTIVE To determine the effect of cyclophosphamide and prednisone on progressive renal failure and on nephrotic features in patients with membranous glomerulonephritis. DESIGN Prospective, nonrandomized time series. SETTING Outpatient clinic at a university medical center. PATIENTS Eleven consecutive patients with biopsy-proven membranous glomerulonephritis and rising plasma creatinine levels over at least 6 months. INTERVENTION Cyclophosphamide and prednisone in ten patients and cyclophosphamide alone in one patient. MEASUREMENTS AND MAIN RESULTS In ten patients treated with both agents, the median plasma creatinine rose 53 mumol/L (0.6 mg/dL) over the months before treatment from 141 to 194 mumol/L (1.6 to 2.2 mg/dL) (95% CI, 27 to 141 mumol/L; P = 0.002). After combined therapy for 6 months, the median plasma creatinine fell to 133 mumol/L (1.5 mg/dL) for a median decline of 62 mumol/L (0.7 mg/dL) (CI, 44 to 150 mumol/L; P = 0.006). Pretreatment plasma creatinine levels, which ranged from 159 to 371 mumol/L (1.8 to 4.2 mg/dL), decreased in the ten patients by 6 months and remained stable in seven of the eight patients followed 24 to 54 months after therapy was completed. The median urine protein excretion decreased by 9.6 g/d with 12 months of therapy in the ten patients from 11.9 to 2.3 g/d (CI, 6.0 to 15.1 g/d; P less than 0.001). The median plasma albumin rose by 14 g/L from 24 to 38 g/L (CI, 11 to 19 g/L; P less than 0.001). The median plasma cholesterol fell by 3.26 mumol/L (140 mg/dL) from 10.45 to 6.52 mumol/L (405 to 252 mg/dL) (CI, 1.42 to 7.16 mumol/L; P = 0.01). One patient who had a relapse 30 months after completing therapy responded to re-treatment with renal function and nephrotic variables returning toward normal. The eleventh patient received cyclophosphamide alone and had a course similar to that of the combined therapy group. CONCLUSION Cyclophosphamide plus prednisone can promote prolonged remissions in membranous glomerulonephritis even when renal function is already declining.


The American Journal of Medicine | 1982

Disseminated listeriosis presenting as acute hepatitis: Case reports and review of hepatic involvement in listeriosis

Victor L. Yu; William P. Miller; Edward J. Wing; Joseph Romano; Cesar A. Ruiz; Frank J. Bruns

We report three cases of disseminated listeriosis that presented as acute hepatitis characterized by striking increase of liver function test values and fever. Peak serum transaminases (SGOT) for each of three patients were 5,380, 2,350, and 443 mu/ml respectively. The correct diagnosis was not suspected in any of the patients until blood and cerebrospinal fluid cultures obtained routinely in the course of evaluation for fever grew Listeria monocytogenes. When antibiotic therapy was instituted, serum transaminase values plummeted in two patients; these two were eventually cured of their infection. The third patient succumbed to his infection; postmortem examination showed miliary abscesses of the liver which revealed L. monocytogenes. Review of the literature for previous reports of hepatic involvement in adult patients with listeriosis shows that hepatitis is an unusual mode of presentation. However, since we observed these three cases over a one-year period, we suspect this may not be an uncommon occurrence.


The American Journal of Medicine | 1989

Long-term follow-up of aggressively treated idiopathic rapidly progressive glomerulonephritis.

Frank J. Bruns; Sheldon Adler; Donald S. Fraley; David P. Segel

PURPOSE We wanted to examine the long-term effects of aggressively treating idiopathic rapidly progressive glomerulonephritis (RPGN), with a particular focus on clinically characterizing the patient population, assessing the short- and long-term effects of therapy on renal function, and determining complications of the therapy. PATIENTS AND METHODS Twenty-three consecutive patients with RPGN were treated and followed from one to 11 years. On renal biopsy, 13 had immune complexes, eight had no immune complexes, and two had antiglomerular basement membrane deposits. All had greater than 25 percent crescents and 19 of 23 had greater than 50 percent crescents. Every patient responded on a short-term basis to either large-dose pulse methylprednisolone or plasma exchange, with reduction of the mean plasma creatinine level from 6.5 +/- 2.0 mg/dl to 2.9 +/- 1.0 mg/dl (p less than 0.001). Each patient received oral prednisone and all but one received cyclophosphamide. RESULTS Three died of non-renal causes. Fifty percent of the remaining 20 patients maintained stable renal function for at least two years. Four of nine patients followed-up for longer than two years had a relapse, but all responded again to therapy. No characteristic clinical symptoms predicting relapse were found, although nearly all had hematuria and proteinuria. Complications of therapy were frequent and may have contributed to death in two patients. CONCLUSION Thus, long remissions are seen in most patients with RPGN treated aggressively.


American Journal of Kidney Diseases | 1984

The Use of Streptokinase to Treat Renal Artery Thromboembolism

Alan Steckel; James R. Johnston; Donald S. Fraley; Frank J. Bruns; David P. Segel; Sheldon Adler

The effects of streptokinase are difficult to determine. Furthermore, it has toxic side effects, and renal function may not recover from its use. However, because of favorable experiences with this drug in the early treatment of venous thromboembolism and following myocardial infarction, as well as the favorable findings with early perfusion in the dog model, the use of local streptokinase may be justified if the infusion is begun early, preferably within four to six hours.


American Journal of Kidney Diseases | 1988

Rupture of Ovarian Cyst: Massive Hemoperitoneum in Continuous Ambulatory Peritoneal Dialysis Patients: Diagnosis and Treatment

Donald S. Fraley; James R. Johnston; Frank J. Bruns; Sheldon Adler; David R Segel

Two women on continuous ambulatory peritoneal dialysis (CAPD) developed recurrent episodes of hemoperitoneum while in the reproductive age group. Initially, both were thought to have mechanical problems with the peritoneal catheter system. A laparotomy was performed in the first patient, and a bleeding ovarian cyst was identified. The second patient had ovarian cysts documented by ultrasound. Thus, abdominal pain and bloody dialysate should not just be ascribed to catheter-related problems. The second patients midcycle bleeding was suppressed with birth control pills.

Collaboration


Dive into the Frank J. Bruns's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sheldon Adler

University of Pittsburgh

View shared research outputs
Top Co-Authors

Avatar

David P. Segel

University of Pittsburgh

View shared research outputs
Top Co-Authors

Avatar

Mark L. Zeidel

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Andrew J. Adler

United States Department of Veterans Affairs

View shared research outputs
Top Co-Authors

Avatar

Geoffrey M. Berlyne

United States Department of Veterans Affairs

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge